AMS IS THE INDUSTRY LEADER IN STRATEGIC INTELLIGENCE SOFTWARE FOR COMBATTING EMERGING HIGH-COST CLAIM ISSUES
What We Do:
AMS delivers crucial insight into catastrophic diagnoses, specialty pharmaceutical, and implant price transparency through clinically vetted, predictive financial analytics with near real-time data.
Who We Serve:
AMS serves multiple stakeholders in the medical claims payment chain, including commercial and governmental payers, Stop Loss and Reinsurance Carriers, MGUs, Medical Management Firms, Health Plans, TPAs, HMOs, Taft-Hartley Plans, workers compensation, and auto medical carriers.
WHO IS USING THE PREDICT SUITE
THE PREDICT SUITE
AMS’ Web-based directories that allow
clients to predict, evaluate and manage high dollar healthcare claims.
PREDICT
Predict costs and clinical treatments for high dollar diagnoses with an on demand decision support solution delivering in-depth clinical information, empirical insight and key financial analytics.
EVALUATE
Evaluate cost data, FDA approved indications, notable off-label usage, adult/pediatric dosing regimens, manufacturer rebates, specialty drug coding and price trends.
MANAGE
Manage highly inflated implant claims by leveraging detailed clinical and financial metrics with the only online, fully- transparent implant cost directory in the industry.
PREDICT SUITE MEMBERSHIP HAS ITS BENEFITS
100%
Reference Rate
Predict Suite Members willing + eager to connect with prospects
99%
Members
Retained
We have retained 99% of our members
13,000
Clinical/Financial Iterations
Including rules, off label + orphan drug uses, price benchmarks and CPT codes
100s
Weekly Hours
Saved
We have saved our clients and members 100s of weekly hours in research and underwriting
AMS Blog
-
Immunotherapies could change kidney cancer care, studies suggest
February 18, 2019
The way doctors typically approach kidney cancer treatment could be evolving. Two separate studies published Saturday in the New England Journal of Medicine showed that renal cell cancer patients had significantly better outcomes when their treatment combined the targeted therapy drug axitinib, or Inlyta, with an immunotherapy — one study used pembrolizumab, or Keytruda, and… Read More » -
CMS unveils CAR-T proposal, with emphasis on patient outcomes
February 15, 2019
Dive Brief: Under a proposal released Friday, Medicare would cover CAR-T cell therapies through a Centers for Medicare and Medicaid Services (CMS) pathway known as Coverage with Evidence Development. The proposal holds a mix of provisions, including that patients must be monitored for at least two years post-treatment. Hospitals administering CAR-T therapy, whether through inpatient or outpatient… Read More »